Shire led to the nullity of the trademark right, Hunterase, against Green Cross
Shire, a company that developed a hunter syndrome treatment ‘Elaprase(idursulfase),’ has succeeded in nullifying a trademark right called ‘Hunterase.’
‘Hunterase(idursulfase)’ developed by Green Cross is a hunter syndrome treatment launched for the 2nd time in the domestic market in 2013.
After...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
